Kawashima Aiko, Tsukamoto Ikuyo, Koyabu Tomoko, Murakami Yasuko, Kawakami Takayo, Kakibuchi Naoko, Takaguchi Kouichi, Kita Keiji, Okita Misako
Department of Natural Science and Ecological Awareness, Graduate School of Humanities and Sciences, Nara Women's University, Kitauoyanishimachi, Nara 630-8506, Japan.
Lipids. 2008 Apr;43(4):325-33. doi: 10.1007/s11745-008-3157-6. Epub 2008 Mar 5.
Eicosapentaenoic acid (EPA) (1.8 g/day) was administered to 12 chronic hepatitis C patients receiving combination therapy of pegylated interferon (PEG-IFN) alpha-2b and ribavirin for 48 weeks (EPA group). Twelve patients were not administered EPA (control group). All patients also received vitamin E and C (300, 600 mg/day, respectively) during the therapy. Serum alanine aminotransferase improved to a normal level in 8 of 12 patients from the EPA group and 6 of 12 patients from the control group after 12 weeks. Lymphocyte counts decreased significantly after 8 weeks in the control group, but not the EPA group. T-helper (Th) 1 decreased after 4 weeks in the control group, but not in the EPA group (two-way ANOVA; P < 0.05). Th1/Th2 ratios were elevated in 9 of 12 patients in the EPA group, and 3 out of 12 in the control group (P < 0.05) after 8 weeks. After 12 weeks, the arachidonic acid/EPA molar ratio of erythrocyte membrane phospholipid correlated negatively with the leukocyte count (n = 24, r = -0.439, P < 0.05) and the neutrophil count (n = 24, r = -0.671, P < 0.02). The hemoglobin level improved after 48 weeks compared with 24 weeks in only the EPA group. These findings suggest that EPA supplementation may be useful in therapy for chronic hepatitis C.
将二十碳五烯酸（EPA）（1.8克/天）给予12例接受聚乙二醇化干扰素（PEG-IFN）α-2b和利巴韦林联合治疗48周的慢性丙型肝炎患者（EPA组）。12例患者未给予EPA（对照组）。所有患者在治疗期间还接受了维生素E和C（分别为300、600毫克/天）。12周后，EPA组12例患者中有8例、对照组12例患者中有6例血清丙氨酸氨基转移酶恢复至正常水平。8周后，对照组淋巴细胞计数显著下降，而EPA组未出现此情况。4周后，对照组辅助性T细胞（Th）1减少，而EPA组未减少（双向方差分析；P<0.05）。8周后，EPA组12例患者中有9例、对照组12例患者中有3例Th1/Th2比值升高（P<0.05）。12周后，红细胞膜磷脂的花生四烯酸/EPA摩尔比与白细胞计数（n = 24，r = -0.439，P<0.05）和中性粒细胞计数（n = 24，r = -0.671，P<0.02）呈负相关。仅EPA组在48周后的血红蛋白水平较24周时有所改善。这些发现表明，补充EPA可能对慢性丙型肝炎的治疗有益。
